Optalert
BiotechnologyView the employees at
Optalert-
Hedi Ziv Out of the box thinker and innovator
-
Greater Melbourne Area
-
Rising Star
Sidnei Canhedo Business Development Executive at Optalert-
Sydney, New South Wales, Australia
-
Rising Star
Murray Johns Chief scientist and Company Director at OPTALERT Pty Ltd-
Rising Star
Kolya Haisken-De New Software Developer at Optalert Limited-
Rising Star
Matthew Kiernan Director, Discovery and Translation Brain and Mind Centre, University of Sydney-
Greater Sydney Area
-
Top 10%
Overview
Optalert developed the world’s leading algorithm to quantify the deterioration in cognitive brain function due to drowsiness and created the Johns Drowsiness Scale (JDS) which remains the only scientifically proven, objective measurement of drowsiness. The JDS is used worldwide in research for accurately quantifying drowsiness levels, and in Optalert’s early-warning drowsiness detection systems to protect thousands of lives and valuable company assets across multiple industries. Our clients include BHP Billiton, Vale and NASA. Our research partners include the Harvard Medical School, Monash University, and the University of Queensland. Optalert is a Medical Technology company pioneering the use of Blepharometry (the measurement of blinks) to measure drowsiness. Optalert discovered a key biomarker for drowsiness, the connection between brain function and eyelid movement. Optalert is now turning its extensive expertise in Blepharometry and Artificial Intelligence to identify the biomarkers for other degradations to neurological brain function in conditions such as Epilepsy (due to onset of seizures), ADHD, Parkinson’s, Alzheimer’s, TBI, concussion and motor neuron disease.
-